High ¹²³I-MIBG Uptake in Neuroblastic Tumours Indicates Unfavourable Histopathology

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2013 Jul 17

PMID 23857458

Citations 9

Authors

Wolfgang Peter Fendler

Henriette Ingrid Melzer

Christoph Walz

Dietrich von Schweinitz

Eva Coppenrath

Irene Schmid

Peter Bartenstein

Thomas Pfluger

Affiliations

Soon will be listed here.

Abstract

Purpose: Scintigraphy using (123)I-metaiodobenzylguanidine ((123)I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on (123)I-MIBG SPECT and histopathology of neuroblastic tumours.

Methods: (123)I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic tumour and compared to histopathology after surgical resection or biopsy at a mean of 2 weeks after SPECT. For each lesion International Neuroblastoma Pathology Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. Also, the presence or absence of MYCN amplification, p1 deletion, urine catecholamine and neuron-specific enolase blood levels at the time of scanning were recorded.

Results: In the 55 patients, 61 lesions were evaluated with (123)I-MIBG SPECT and corresponding histopathological findings were reviewed (11 ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). Intense (123)I-MIBG uptake was found in tumour tissue with a high mitotic activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were (123)I-MIBG-negative.

Conclusion: In paediatric patients with peripheral neuroblastic tumours, strong (123)I-MIBG uptake indicates unfavourable histopathology. High uptake was seen in neuroblastomas and in tumours with a high mitotic activity.

Citing Articles

Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine.

Yokoyama K, Matsuki M, Isozaki T, Ito K, Imokawa T, Ozawa A Jpn J Radiol. 2025; .

PMID: 39794659 DOI: 10.1007/s11604-025-01732-6.

Adrenal ganglioneuroma with nodal metastases on I-MIBG SPECT/CT and F-FDG PET/CT.

Tsukamoto S, Kawabata K, Ito S, Ando S, Kuriyama K, Morooka S Radiol Case Rep. 2024; 19(11):5128-5132.

PMID: 39263517 PMC: 11388043. DOI: 10.1016/j.radcr.2024.07.128.

Pediatric mediastinal masses.

Sreedher G, Tadros S, Janitz E Pediatr Radiol. 2022; 52(10):1935-1947.

PMID: 35674800 DOI: 10.1007/s00247-022-05409-4.

Adrenal ganglioneuroma: Prognostic factors (Review).

Sandru F, Dumitrascu M, Petca A, Carsote M, Petca R, Oproiu A Exp Ther Med. 2021; 22(5):1338.

PMID: 34630692 PMC: 8495554. DOI: 10.3892/etm.2021.10773.

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.

Samim A, Tytgat G, Bleeker G, Wenker S, Chatalic K, Poot A J Pers Med. 2021; 11(4).

PMID: 33916640 PMC: 8066332. DOI: 10.3390/jpm11040270.

References

Melzer H, Coppenrath E, Schmid I, Albert M, von Schweinitz D, Tudball C . ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011; 38(9):1648-58. DOI: 10.1007/s00259-011-1843-8. View

Maris J . The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7-13. DOI: 10.1097/01.mop.0000150631.60571.89. View

Okuyama C, Ushijima Y, Watanabe K, Sugihara H, Nishimura T . [Iodine-123-MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics]. Kaku Igaku. 1999; 36(8):827-34. View

Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View

Wenzel A, Cziepluch C, Hamann U, SCHURMANN J, Schwab M . The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J. 1991; 10(12):3703-12. PMC: 453104. DOI: 10.1002/j.1460-2075.1991.tb04938.x. View

FEINE U, Muller-Schauenburg W, Treuner J, Klingebiel T . Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol. 1987; 15(4):181-7. DOI: 10.1002/mpo.2950150408. View

Goto S, Umehara S, Gerbing R, Stram D, Brodeur G, Seeger R . Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001; 92(10):2699-708. DOI: 10.1002/1097-0142(20011115)92:10<2699::aid-cncr1624>3.0.co;2-a. View

Lu M, Liu Y, Chang H, Jou S, Yang Y, Lin K . Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2012; 54(1):42-9. DOI: 10.2967/jnumed.112.102772. View

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View

10.

George R, Perez-Atayde A, Yao X, London W, Shamberger R, Neuberg D . Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2011; 59(3):506-10. DOI: 10.1002/pbc.24013. View

11.

Freitas J . Adrenal cortical and medullary imaging. Semin Nucl Med. 1995; 25(3):235-30. DOI: 10.1016/s0001-2998(95)80013-1. View

12.

Mairs R, Livingstone A, Gaze M, Wheldon T, Barrett A . Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994; 70(1):97-101. PMC: 2033329. DOI: 10.1038/bjc.1994.256. View

13.

Sharp S, Gelfand M, Shulkin B . Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011; 41(5):345-53. DOI: 10.1053/j.semnuclmed.2011.05.001. View

14.

Shulkin B, Hutchinson R, Castle V, Yanik G, Shapiro B, Sisson J . Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996; 199(3):743-50. DOI: 10.1148/radiology.199.3.8637999. View

15.

Vik T, Pfluger T, Kadota R, Castel V, Tulchinsky M, Alonso Farto J . (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52(7):784-90. DOI: 10.1002/pbc.21932. View

16.

Grosfeld J, Skinner M, Rescorla F, West K, Scherer 3rd L . Mediastinal tumors in children: experience with 196 cases. Ann Surg Oncol. 1994; 1(2):121-7. DOI: 10.1007/BF02303555. View

17.

Biasotti S, Garaventa A, Villavecchia G, Cabria M, Nantron M, De Bernardi B . False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000; 35(2):153-5. DOI: 10.1002/1096-911x(200008)35:2<153::aid-mpo18>3.0.co;2-7. View

18.

Shulkin B, Shapiro B . Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998; 39(4):679-88. View

19.

Taggart D, London W, Schmidt M, Dubois S, Monclair T, Nakagawara A . Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011; 29(33):4358-64. PMC: 3221520. DOI: 10.1200/JCO.2011.35.9570. View

20.

White P, Maris J, Beltinger C, SULMAN E, Marshall H, Fujimori M . A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A. 1995; 92(12):5520-4. PMC: 41727. DOI: 10.1073/pnas.92.12.5520. View